

PANELISTS

JOHN FRANKEL

John Frankel is a technology investor. He is passionate about working with founders that are building the big businesses of tomorrow. He founded ff Venture Capital in 2008 to work with founders who share this vision, which has since funded over 100 seed and early-stage companies that have in turn created thousands of jobs and impacted the lives of millions.

While ff Venture Capital's investments span a number of industries, John is particularly fascinated by applied artificial intelligence, encompassing drones, robotics, financial services technology and cyber security. Over the years, John has served on the boards of dozens of companies as well as the NYU Tandon School of Engineering, to help in further fostering the New York City ecosystem.

Prior to founding ffVC, John had a long career at Goldman Sachs in a variety of roles that involved technology development, business reengineering, and capital markets. He has had the unique opportunity to work closely with some of the world's leading investors, and as a result has developed a keen understanding of emerging technologies and portfolio risk/return management.

After graduating from New College Oxford in 1982 with a Masters in Mathematics and Philosophy, John worked at Arthur Anderson and qualified as a Fellow Chartered Accountant. Today, John enjoys traveling the world and is blessed with five amazing children and six incredible grandchildren.

JIM GOLUBIESKI

Jim is President of Foundation for Health Advancement and its affiliates, New Jersey Health Foundation and Foundation Venture Capital Group, LLC. These companies support the development of health-related research and start-up companies in New Jersey by providing grants through the Research Grant Program, Innovation Grant Program and investment funding.

He works closely with the companies in which Foundation Venture has invested, sits on their Boards and provides guidance in helping them to develop their businesses toward commercialization.

Previously he had been CFO of Array Medical, Inc., a medical device start-up company that developed a groundbreaking blood test to test platelet function and was subsequently acquired. He also served in various executive roles and board member at Glendale National Bank, Glendale Investment Corp., Glendale Mortgage Services, Inc. and Glendale Bancorp, which was acquired by Mellon Financial. Jim began his career at KPMG as a certified public accountant.

MICHAEL JOHNSON

Dr. Michael Johnson is a 2017 and 2019 Forbes 30 Under 30 honoree and the CEO and Co-Founder of Visikol Inc., which is a bio-imaging company that spun out of Rutgers University in 2016 and that Michael founded along with his fellow PhD candidate Thomas Villani and colleague Nick Crider.

Michael has a diverse background with experiences in both the technical and business considerations of running a biotech business. Following his undergraduate degree in biology at Muhlenberg College, Michael spent three years in various roles at Johnson & Johnson while concurrently pursuing a PhD in applied microbiology at Rutgers University.

Michael's research background has focused on a wide-range of projects from remote sensing research with NASA to building light sheet microscopes and producing biofuels. Prior to launching Visikol, Michael has worked on several other biotech-based entrepreneurial pursuits and is very passionate about translating cutting edge research into life-changing commercial technologies.

BRIAN MULHALL

Brian was the founder and CEO of Whitehouse Analytical Laboratories, an FDA regulated testing facility that served the quality control testing needs of the pharmaceutical and biotechnology industries. Over the course of 13 years, Brian led all phases of the company's growth and expansion. An organization that started in 2002 with 3,000 square feet of empty lab space, 3 employees and a unique focus on pharmaceutical container testing grew exponentially under Brian's leadership. By 2015, Whitehouse Labs was operating in a state-of-the-art laboratory facility that exceeded 24,000 square feet, had 48 full time employees and offered a suite of services in Pharma Container Testing, Package Testing, Raw Material Analysis & Qualification, Technical Support and Testing and Container Closure Integrity Testing. In late 2015, Whitehouse Analytical Laboratories was acquired by Albany Molecular Research (AMRI) a publicly traded pharma services company that supported many aspects of the drug discovery and approval process for its pharma clients.

Over the past five years, Brian has served as an equity investor in pharma related start-up companies and currently holds a position, and serves as a consultant for Visikol. In early 2019, Brian, along with a group of experienced executives, acquired Leak Detection Associates (LDA), a manufacturer of helium-based container and package testing systems marketed and used by the pharma, biotech and packaged food industries to ensure the integrity of their package systems. Brian has taken lead of the operation on both a macro and micro level with a strong emphasis on global expansion of the LDA brand. Prior to his time at Whitehouse Labs, he held numerous management positions at both Ferring Pharmaceutical and Organon — a division of Schering-Plough.

ARI RABBAN

Ari is the CEO & Co-Founder of Phone.com, Inc. a leading New Jersey-based cloud communications service provider. Ari is a veteran of the IP-communications industry. He served a senior executive at VocalTec Communications, the Internet telephony industry pioneer, and helped co-found, manage and sell 3 pioneering VoIP businesses. He also served as a strategy manager for Lucent Technologies.

Ari currently serves on the boards of USPharma Labs and the New Jersey Technology Council. He also mentors aspiring entrepreneurs. He holds an MBA from Carnegie Mellon University, and a law degree and BA in Economics, both from Tel Aviv University.

MODERATOR

MIKE WILEY

Mike Wiley is Vice President of the New Jersey Health Foundation and its affiliate, Foundation Venture Capital Group, LLC. These organizations provide funding and/or pre-seed investments for health-related projects and start-up companies founded by researchers at the following affiliated organizations: Kessler Foundation, New Jersey Institute of Technology, Princeton University, Rowan University, Rutgers University and Stevens Institute of Technology.

Mike assists the Foundation Venture Capital Group's health-related portfolio companies by providing funding and assisting with the various strategic, operational and back office management issues associated with developing and growing early-stage health-related companies.

Prior to joining the New Jersey Health Foundation and the Foundation Venture Capital Group, his experience included: business development, new venture financing, program/product development, commercial contracting, and intellectual property/technology licensing for organizations such as the New Jersey Economic Development Authority (Edison Innovation Fund), Avaya, Rutgers University's Office of Corporate Liaison and Technology Transfer, and Lucent Technologies. Mike has earned B.A., M.B.A. and J.D. degrees from West Virginia University.